Possible pathophysiologic roles of neurotransmitter systems in men with lifelong premature ejaculation: a scoping review

Lifelong premature ejaculation (LPE) is a subtype of premature ejaculation. Genetic research on LPE has primarily focused on neurotransmitters such as serotonin, dopamine, and norepinephrine, whereas LPE treatment studies have focused on drugs such as selective serotonin reuptake inhibitors. However...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sexual medicine reviews 2024-09, Vol.12 (4), p.638-651
Hauptverfasser: van Raaij, Joost J, Serefoglu, Ege Can, van Amelsvoort, Thérèse A M J, Janssen, Paddy K C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 651
container_issue 4
container_start_page 638
container_title Sexual medicine reviews
container_volume 12
creator van Raaij, Joost J
Serefoglu, Ege Can
van Amelsvoort, Thérèse A M J
Janssen, Paddy K C
description Lifelong premature ejaculation (LPE) is a subtype of premature ejaculation. Genetic research on LPE has primarily focused on neurotransmitters such as serotonin, dopamine, and norepinephrine, whereas LPE treatment studies have focused on drugs such as selective serotonin reuptake inhibitors. However, findings from genetic association and pharmacotherapeutic studies have been inconsistent. To provide a quality overview of neurobiological targets that are potentially associated with LPE by investigating genetic association and pharmacotherapeutic studies. This scoping review was conducted per the PRISMA-ScR tool (Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews). Five databases were searched in March 2023 without timeline- or language-related restrictions. After deduplication, 3949 records were obtained for review. Following screening and full-text review with citation tracking, 52 studies were included: 18 genetic and 34 pharmacotherapy studies. Serotonergic targets, such as the serotonin transporter and pre- and postsynaptic serotonergic receptors, were most often associated with LPE in genetic and pharmacotherapeutic studies. Mixed results were found among polymorphisms within genetic studies. This mechanism is in accordance with pharmacotherapeutic studies, as the highest efficacy was found for potent serotonergic antidepressants. Successful treatment was also observed with medication acting on phosphodiesterase-5 enzyme, such as tadalafil and vardenafil. Analyses of other genetic association studies did not yield any further evidence for associated targets. This review is the first comprehensive scoping review on LPE. We found that serotonergic targets are most often associated with LPE, suggesting that the serotonergic pathway is a predisposing factor in LPE. Furthermore, there is some evidence for phosphodiesterase 5 inhibitors, which should be investigated. Other previously investigated neurobiological targets appear less likely to contribute to LPE. Future studies should focus on multiple targets, ideally in a genome-wide association study design.This review has been registered with the Open Science Framework (doi:10.17605/OSF.IO/JUQSD).
doi_str_mv 10.1093/sxmrev/qeae048
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3083216795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3083216795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c220t-e5f39bc31ee5e3769d5c1e92c4ecd1257b6f1cf5e3cbf98c192a900e95f127ce3</originalsourceid><addsrcrecordid>eNo9kE1PAjEQhhujEYNcPZoevSz0Y7tQb4b4lZDoQc-bbplCSXe7tF2Bf-8akLnMJPPMm8mD0B0lY0okn8R9HeBnsgUFJJ9doBtGBMmIYPTyPFM-QKMYN6QvKTnP5TUacEl4Tklxg_afPkZbOcCtSmvfrg_ReudXVuPgHUTsDW6gCz4F1cTapgQBx0NMUEdsG1xDg3c2rbGzBpxvVrgNUKvUBcCwUbpzKlnfPGKFo_at7YH-ZQu7W3RllIswOvUh-n55_pq_ZYuP1_f50yLTjJGUgTBcVppTAAF8Wsil0BQk0znoJWViWhWGatPvdGXkTFPJlCQEpDCUTTXwIXo45rbBbzuIqaxt1OCcasB3seRkxhktplL06PiI6tBLCWDKNthahUNJSfknvDwKL0_C-4P7U3ZX1bA84_96-S9HRYKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3083216795</pqid></control><display><type>article</type><title>Possible pathophysiologic roles of neurotransmitter systems in men with lifelong premature ejaculation: a scoping review</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>van Raaij, Joost J ; Serefoglu, Ege Can ; van Amelsvoort, Thérèse A M J ; Janssen, Paddy K C</creator><creatorcontrib>van Raaij, Joost J ; Serefoglu, Ege Can ; van Amelsvoort, Thérèse A M J ; Janssen, Paddy K C</creatorcontrib><description>Lifelong premature ejaculation (LPE) is a subtype of premature ejaculation. Genetic research on LPE has primarily focused on neurotransmitters such as serotonin, dopamine, and norepinephrine, whereas LPE treatment studies have focused on drugs such as selective serotonin reuptake inhibitors. However, findings from genetic association and pharmacotherapeutic studies have been inconsistent. To provide a quality overview of neurobiological targets that are potentially associated with LPE by investigating genetic association and pharmacotherapeutic studies. This scoping review was conducted per the PRISMA-ScR tool (Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews). Five databases were searched in March 2023 without timeline- or language-related restrictions. After deduplication, 3949 records were obtained for review. Following screening and full-text review with citation tracking, 52 studies were included: 18 genetic and 34 pharmacotherapy studies. Serotonergic targets, such as the serotonin transporter and pre- and postsynaptic serotonergic receptors, were most often associated with LPE in genetic and pharmacotherapeutic studies. Mixed results were found among polymorphisms within genetic studies. This mechanism is in accordance with pharmacotherapeutic studies, as the highest efficacy was found for potent serotonergic antidepressants. Successful treatment was also observed with medication acting on phosphodiesterase-5 enzyme, such as tadalafil and vardenafil. Analyses of other genetic association studies did not yield any further evidence for associated targets. This review is the first comprehensive scoping review on LPE. We found that serotonergic targets are most often associated with LPE, suggesting that the serotonergic pathway is a predisposing factor in LPE. Furthermore, there is some evidence for phosphodiesterase 5 inhibitors, which should be investigated. Other previously investigated neurobiological targets appear less likely to contribute to LPE. Future studies should focus on multiple targets, ideally in a genome-wide association study design.This review has been registered with the Open Science Framework (doi:10.17605/OSF.IO/JUQSD).</description><identifier>ISSN: 2050-0513</identifier><identifier>ISSN: 2050-0521</identifier><identifier>EISSN: 2050-0521</identifier><identifier>DOI: 10.1093/sxmrev/qeae048</identifier><identifier>PMID: 39034106</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Humans ; Male ; Neurotransmitter Agents - physiology ; Premature Ejaculation - drug therapy ; Premature Ejaculation - genetics ; Premature Ejaculation - physiopathology ; Selective Serotonin Reuptake Inhibitors - therapeutic use</subject><ispartof>Sexual medicine reviews, 2024-09, Vol.12 (4), p.638-651</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of The International Society of Sexual Medicine.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c220t-e5f39bc31ee5e3769d5c1e92c4ecd1257b6f1cf5e3cbf98c192a900e95f127ce3</cites><orcidid>0000-0002-3050-2728 ; 0000-0002-0940-4840</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39034106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Raaij, Joost J</creatorcontrib><creatorcontrib>Serefoglu, Ege Can</creatorcontrib><creatorcontrib>van Amelsvoort, Thérèse A M J</creatorcontrib><creatorcontrib>Janssen, Paddy K C</creatorcontrib><title>Possible pathophysiologic roles of neurotransmitter systems in men with lifelong premature ejaculation: a scoping review</title><title>Sexual medicine reviews</title><addtitle>Sex Med Rev</addtitle><description>Lifelong premature ejaculation (LPE) is a subtype of premature ejaculation. Genetic research on LPE has primarily focused on neurotransmitters such as serotonin, dopamine, and norepinephrine, whereas LPE treatment studies have focused on drugs such as selective serotonin reuptake inhibitors. However, findings from genetic association and pharmacotherapeutic studies have been inconsistent. To provide a quality overview of neurobiological targets that are potentially associated with LPE by investigating genetic association and pharmacotherapeutic studies. This scoping review was conducted per the PRISMA-ScR tool (Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews). Five databases were searched in March 2023 without timeline- or language-related restrictions. After deduplication, 3949 records were obtained for review. Following screening and full-text review with citation tracking, 52 studies were included: 18 genetic and 34 pharmacotherapy studies. Serotonergic targets, such as the serotonin transporter and pre- and postsynaptic serotonergic receptors, were most often associated with LPE in genetic and pharmacotherapeutic studies. Mixed results were found among polymorphisms within genetic studies. This mechanism is in accordance with pharmacotherapeutic studies, as the highest efficacy was found for potent serotonergic antidepressants. Successful treatment was also observed with medication acting on phosphodiesterase-5 enzyme, such as tadalafil and vardenafil. Analyses of other genetic association studies did not yield any further evidence for associated targets. This review is the first comprehensive scoping review on LPE. We found that serotonergic targets are most often associated with LPE, suggesting that the serotonergic pathway is a predisposing factor in LPE. Furthermore, there is some evidence for phosphodiesterase 5 inhibitors, which should be investigated. Other previously investigated neurobiological targets appear less likely to contribute to LPE. Future studies should focus on multiple targets, ideally in a genome-wide association study design.This review has been registered with the Open Science Framework (doi:10.17605/OSF.IO/JUQSD).</description><subject>Humans</subject><subject>Male</subject><subject>Neurotransmitter Agents - physiology</subject><subject>Premature Ejaculation - drug therapy</subject><subject>Premature Ejaculation - genetics</subject><subject>Premature Ejaculation - physiopathology</subject><subject>Selective Serotonin Reuptake Inhibitors - therapeutic use</subject><issn>2050-0513</issn><issn>2050-0521</issn><issn>2050-0521</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PAjEQhhujEYNcPZoevSz0Y7tQb4b4lZDoQc-bbplCSXe7tF2Bf-8akLnMJPPMm8mD0B0lY0okn8R9HeBnsgUFJJ9doBtGBMmIYPTyPFM-QKMYN6QvKTnP5TUacEl4Tklxg_afPkZbOcCtSmvfrg_ReudXVuPgHUTsDW6gCz4F1cTapgQBx0NMUEdsG1xDg3c2rbGzBpxvVrgNUKvUBcCwUbpzKlnfPGKFo_at7YH-ZQu7W3RllIswOvUh-n55_pq_ZYuP1_f50yLTjJGUgTBcVppTAAF8Wsil0BQk0znoJWViWhWGatPvdGXkTFPJlCQEpDCUTTXwIXo45rbBbzuIqaxt1OCcasB3seRkxhktplL06PiI6tBLCWDKNthahUNJSfknvDwKL0_C-4P7U3ZX1bA84_96-S9HRYKQ</recordid><startdate>20240925</startdate><enddate>20240925</enddate><creator>van Raaij, Joost J</creator><creator>Serefoglu, Ege Can</creator><creator>van Amelsvoort, Thérèse A M J</creator><creator>Janssen, Paddy K C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3050-2728</orcidid><orcidid>https://orcid.org/0000-0002-0940-4840</orcidid></search><sort><creationdate>20240925</creationdate><title>Possible pathophysiologic roles of neurotransmitter systems in men with lifelong premature ejaculation: a scoping review</title><author>van Raaij, Joost J ; Serefoglu, Ege Can ; van Amelsvoort, Thérèse A M J ; Janssen, Paddy K C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c220t-e5f39bc31ee5e3769d5c1e92c4ecd1257b6f1cf5e3cbf98c192a900e95f127ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Humans</topic><topic>Male</topic><topic>Neurotransmitter Agents - physiology</topic><topic>Premature Ejaculation - drug therapy</topic><topic>Premature Ejaculation - genetics</topic><topic>Premature Ejaculation - physiopathology</topic><topic>Selective Serotonin Reuptake Inhibitors - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Raaij, Joost J</creatorcontrib><creatorcontrib>Serefoglu, Ege Can</creatorcontrib><creatorcontrib>van Amelsvoort, Thérèse A M J</creatorcontrib><creatorcontrib>Janssen, Paddy K C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Sexual medicine reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Raaij, Joost J</au><au>Serefoglu, Ege Can</au><au>van Amelsvoort, Thérèse A M J</au><au>Janssen, Paddy K C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Possible pathophysiologic roles of neurotransmitter systems in men with lifelong premature ejaculation: a scoping review</atitle><jtitle>Sexual medicine reviews</jtitle><addtitle>Sex Med Rev</addtitle><date>2024-09-25</date><risdate>2024</risdate><volume>12</volume><issue>4</issue><spage>638</spage><epage>651</epage><pages>638-651</pages><issn>2050-0513</issn><issn>2050-0521</issn><eissn>2050-0521</eissn><abstract>Lifelong premature ejaculation (LPE) is a subtype of premature ejaculation. Genetic research on LPE has primarily focused on neurotransmitters such as serotonin, dopamine, and norepinephrine, whereas LPE treatment studies have focused on drugs such as selective serotonin reuptake inhibitors. However, findings from genetic association and pharmacotherapeutic studies have been inconsistent. To provide a quality overview of neurobiological targets that are potentially associated with LPE by investigating genetic association and pharmacotherapeutic studies. This scoping review was conducted per the PRISMA-ScR tool (Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews). Five databases were searched in March 2023 without timeline- or language-related restrictions. After deduplication, 3949 records were obtained for review. Following screening and full-text review with citation tracking, 52 studies were included: 18 genetic and 34 pharmacotherapy studies. Serotonergic targets, such as the serotonin transporter and pre- and postsynaptic serotonergic receptors, were most often associated with LPE in genetic and pharmacotherapeutic studies. Mixed results were found among polymorphisms within genetic studies. This mechanism is in accordance with pharmacotherapeutic studies, as the highest efficacy was found for potent serotonergic antidepressants. Successful treatment was also observed with medication acting on phosphodiesterase-5 enzyme, such as tadalafil and vardenafil. Analyses of other genetic association studies did not yield any further evidence for associated targets. This review is the first comprehensive scoping review on LPE. We found that serotonergic targets are most often associated with LPE, suggesting that the serotonergic pathway is a predisposing factor in LPE. Furthermore, there is some evidence for phosphodiesterase 5 inhibitors, which should be investigated. Other previously investigated neurobiological targets appear less likely to contribute to LPE. Future studies should focus on multiple targets, ideally in a genome-wide association study design.This review has been registered with the Open Science Framework (doi:10.17605/OSF.IO/JUQSD).</abstract><cop>Netherlands</cop><pmid>39034106</pmid><doi>10.1093/sxmrev/qeae048</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-3050-2728</orcidid><orcidid>https://orcid.org/0000-0002-0940-4840</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2050-0513
ispartof Sexual medicine reviews, 2024-09, Vol.12 (4), p.638-651
issn 2050-0513
2050-0521
2050-0521
language eng
recordid cdi_proquest_miscellaneous_3083216795
source MEDLINE; Oxford University Press Journals All Titles (1996-Current)
subjects Humans
Male
Neurotransmitter Agents - physiology
Premature Ejaculation - drug therapy
Premature Ejaculation - genetics
Premature Ejaculation - physiopathology
Selective Serotonin Reuptake Inhibitors - therapeutic use
title Possible pathophysiologic roles of neurotransmitter systems in men with lifelong premature ejaculation: a scoping review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A29%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Possible%20pathophysiologic%20roles%20of%20neurotransmitter%20systems%20in%20men%20with%20lifelong%20premature%20ejaculation:%20a%20scoping%20review&rft.jtitle=Sexual%20medicine%20reviews&rft.au=van%20Raaij,%20Joost%20J&rft.date=2024-09-25&rft.volume=12&rft.issue=4&rft.spage=638&rft.epage=651&rft.pages=638-651&rft.issn=2050-0513&rft.eissn=2050-0521&rft_id=info:doi/10.1093/sxmrev/qeae048&rft_dat=%3Cproquest_cross%3E3083216795%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3083216795&rft_id=info:pmid/39034106&rfr_iscdi=true